New Trials in Lung Cancer: Could Your Patients Benefit?

Adult patients with this type of cancer can join a randomized, controlled, phase 3 study assessing whether an investigational drug called V940 added toV940 is an individualized neoantigen therapy designed to generate T-cell antitumor responses targeted to a patient's specific mutation profile.

MK-2870 delivers a cytotoxin to cancer cells by binding to trophoblast cell-surface antigen 2, known to promote tumor cell growth and metastasis. For up to 2 years, half of participants will receive MK-2870 by IV every 2 weeks plus IV pembrolizumab every 6 weeks. The other group will receive only pembrolizumab.

The study, which is planning to recruit 1016 participants, opened across 16 US states and 12 countries worldwide in December 2023. Sites in 11 more US states, the District of Columbia, Brazil, Canada, China, India, and 11 more European countries are gearing up. Adverse events and progression-free survival are the primary endpoints. Overall survival over approximately 3 years and QoL are secondary endpoints.

Source: Healthcare Press (healthcarepress.net)

Lung Carcinoma Cancer Of The Lung Non-Small Cell Lung Cancer Nsclc Small Cell Lung Cancer Small-Cell Lung Cancer Oat Cell Lung Cancer SCLC Biologic Therapy Biologics Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Skin Cancer Malignant Skin Neoplasm Metastasis Metastatic Carcinoma Metastatic Cancer Metastases Genomics Genomic Medicine Lung Toxicology Toxicity

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Lung cancer treatment: Pfizer's Lorbrena extends life in some non-small cell lung cancersKaitlin Sullivan is a contributor for NBCNews.com who has worked with NBC News Investigations. She reports on health, science and the environment and is a graduate of the Craig Newmark Graduate School of Journalism at City University of New York.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

Trials show ‘unprecedented’ pill slowing lung cancer in 60% of patientsLorlatinib is a third-generation ALK inhibitor used as standard first-line treatment for patients with ALK-positive NSCLC or lung cancer.
Source: IntEngineering - 🏆 287. / 63 Read more »

Underrepresentation in clinical trials leads to cancer disparities, says Fox Chase Cancer Center’s Camille RaginWant to reduce racial disparities in cancer? Make clinical trials more diverse, a Fox Chase researcher says.
Source: PhillyDailyNews - 🏆 89. / 67 Read more »

City of Hope’s new blood test for lung cancer will mean more early detectionsCity of Hope has launched a program using a simple blood test to determine is someone might have lung cancer.
Source: ladailynews - 🏆 332. / 59 Read more »

Just 18% of People Who Need Lung Cancer Screening Get ItOnly a fraction of Americans are getting recommended lung cancer screenings, new research shows.
Source: MedicineNet - 🏆 575. / 51 Read more »

Lung organoids reveal how pathogens infect human lung tissueHow do pathogens invade the lungs? Using human lung microtissues, a team at the Biozentrum of the University of Basel has uncovered the strategy used by a dangerous pathogen. The bacterium targets specific lung cells and has developed a sophisticated strategy to break through the lungs' line of defense.
Source: physorg_com - 🏆 388. / 55 Read more »